Synonyms: compound 13 [WO2022034616A1] | JBI589
Compound class:
Synthetic organic
Comment: JBI-589 is an orally bioavailable, pharmacological inhibitor of peptidyl arginine deiminase 4 (PADI4) [2-3]. PADI4 is involved in several biological processes, including neutrophil extracellular trap (NET) formation that is an important component of the innate immune system and defence against invading pathogens. Elevated PADI4 activity can induce dysregulated NETosis that triggers a cascade of inflammatory reactions that can promote autoimmune diseases, cancer cell metastasis, and damage to surrounding tissues. PADI4 inhibitors are being considered for conditons that are associated with NETosis.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
JBI-589 inhibits NET formation in vitro, and provides efficacy in mouse arthritis models in vivo [2]. It has also been reported to inhibit progression of primary tumours and metastases in mouse xenograft models [1]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|